MilliporeSigma, the US and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened a new bioprocessing production center in Daejeon, South Korea, following an investment of more than $350 million. The facility represents the company’s largest Life Science investment in the Asia-Pacific region to date and is designed to expand regional manufacturing capacity for materials used in the development and production of biologic medicines.
Covering approximately 44,500 square meters, the center will supply products for biopharmaceutical manufacturing, serving customers from early process development through commercial-scale production. The investment supports the company’s strategy of manufacturing products closer to the markets where they are used, with the aim of strengthening supply reliability and improving access to critical materials for biopharma manufacturers across Asia-Pacific.
The facility will manufacture cell culture media in dry powder and liquid formats, including customized, pre-GMP small-scale media through the company’s imMEDIAte ADVANTAGE offering. Other products will include process liquids, ready-to-use cleaning-in-place (CIP) solutions, and single-use sterile sampling solutions based on the NovaSeptum Sterile Sampling System.
MilliporeSigma says cell culture media and process liquids manufactured at the Daejeon site will use animal-component-free raw materials and follow consistent global quality standards. The facility is intended to help customers maintain product quality and process consistency as they advance from development to commercial manufacturing.
Digital infrastructure is another central feature of the new center. Integrated systems will support automated data capture and end-to-end batch traceability, improving visibility into manufacturing activities and supporting quality management and regulatory compliance.
Source: drug-dev.com · Image: VP-BTI (aircraft) at Sheremetyevo International Airport pic2 by Alf van Beem, Public domain, via Wikimedia Commons
Use the database as your supply chain compass →
